{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:36:35Z","timestamp":1789918595094,"version":"4.0.1"},"reference-count":38,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of ibalizumab (IBA) in the treatment of HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar (2010 to mid-June 2020) with the search terms TMB-355, TNX-355, and ibalizumab. Other resources included abstracts presented at recent conferences and the manufacturer\u2019s website and prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant English-language articles of studies assessing the efficacy and safety of IBA were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>IBA is a monoclonal antibody that blocks HIV-1 from infecting CD4+ T cells. IBA is approved by the Food and Drug Administration, in combination with other antiretrovirals (ARVs), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant (MDR) HIV-1 infection failing their current ARVs. IBA demonstrated significant and sustained antiviral activity in patients with MDR HIV-1 infection who had advanced disease and limited treatment options. It carries a warning regarding the development of immune reconstitution inflammatory syndrome. Common adverse reactions include diarrhea, dizziness, nausea, and rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>IBA represents an attractive option for treatment-experienced adults with advanced HIV-1 infection who are no longer able to achieve viral suppression on oral ARV therapy alone and who are able to adhere to an infusion therapy every 2 weeks. As with other biologics, there is a potential for the development of antibodies to IBA that can compromise its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>IBA provides a needed treatment option to achieve and maintain viral suppression in heavily treatment-experienced adults with MDR HIV-1 infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020942218","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T17:14:14Z","timestamp":1594660454000},"page":"230-239","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":24,"title":["Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"first","affiliation":[{"name":"Palm Beach Atlantic University Lloyld L. Gregory School of Pharmacy, West Palm Beach, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer H.","family":"Durham","sequence":"additional","affiliation":[{"name":"Auburn University Harrison School of Pharmacy, Auburn, AL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"bibr1-1060028020942218","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed May 1, 2020. http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf"},{"key":"bibr2-1060028020942218","unstructured":"Centers for Disease Control and Prevention. HIV statistics overview. Accessed May 30, 2020. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/index.html#:~:text=At%20the%20end%20of%202016,infections%20had%20not%20been%20diagnosed.&text=In%2050%20states%20and%20the%20District%20of%20Columbia.&text=CDC"},{"key":"bibr3-1060028020942218","unstructured":"OptumRx\u00ae. Trogarzo\u2122 (ibalizumab-uiyk)\u2014new orphan drug approval. Published March 6, 2018. Accessed May 1, 2020. https:\/\/professionals.optumrx.com\/content\/dam\/optum3\/professional-optumrx\/news\/rxnews\/drug-approvals\/drugapprovals_trogarzo_2018-0307.pdf"},{"key":"bibr4-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy463"},{"key":"bibr5-1060028020942218","unstructured":"US Food and Drug Administration. FDA approves new HIV treatment for patients who have limited treatment options. Published March 6, 2018. Accessed May 1, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options?"},{"key":"bibr6-1060028020942218","unstructured":"European Medications Agency. Trogarzo. Accessed May 1, 2020. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/trogarzo"},{"key":"bibr7-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01258-3"},{"key":"bibr8-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00453-10"},{"key":"bibr9-1060028020942218","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2017.02323"},{"key":"bibr10-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182732746"},{"key":"bibr11-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02237-10"},{"key":"bibr12-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00110-19"},{"key":"bibr13-1060028020942218","volume-title":"Poster presented at: Conference on Retroviruses and Opportunistic Infections","author":"Lin HH"},{"key":"bibr14-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"bibr15-1060028020942218","unstructured":"Trogarzo. Package insert. Theratechnologies Inc; 2020."},{"key":"bibr16-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00942-08"},{"key":"bibr17-1060028020942218","unstructured":"Weinheimer S, Cohen Z, Marsolais C, Lewis S. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals [abstract 561]. Poster presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2018; Boston, MA. Accessed May 1, 2020. https:\/\/www.croiconference.org\/abstract\/ibalizumab-susceptibility-patient-hiv-isolates-resistant-antiretrovirals\/"},{"key":"bibr18-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00761-05"},{"key":"bibr19-1060028020942218","unstructured":"Norris D, Morales J, Gathe J, et al. Phase 2 efficacy and safety of the novel entry inhibitor, TNX-355, in combination with optimized background regimen [abstract TUPE0058]. Paper presented at: XVI International AIDS Conference; August 13-18, 2006; Toronto, CA. Accessed May 1, 2020. http:\/\/www.natap.org\/2006\/IAS\/IAS_47.htm"},{"key":"bibr20-1060028020942218","unstructured":"Khanlou H, Gathe JJ, Schrader S, et al. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study [abstract H2-794b]. Paper presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL. Accessed May 1, 2020. http:\/\/www.natap.org\/2011\/ICAAC\/ICAAC_43.htm"},{"key":"bibr21-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx162.093"},{"key":"bibr22-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.729"},{"key":"bibr23-1060028020942218","unstructured":"Emu B, Lalezari J, Kumar P, et al. Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals [abstract 485]. Paper presented at: Conference on Retroviruses and Opportunistic Infections; March 4-7, 2019; Seattle, WA. Accessed May 1, 2020. https:\/\/www.croiconference.org\/sessions\/Ibalizumab-96-week-data-and-efficacy-patients-resistant-common-antiretrovirals"},{"key":"bibr24-1060028020942218","volume-title":"Paper presented at: 17th European AIDS Conference;","author":"Moyle G"},{"key":"bibr25-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1808729"},{"key":"bibr26-1060028020942218","volume-title":"Paper presented at: Conference on Retroviruses and Opportunistic Infections","author":"DeJesus E"},{"key":"bibr27-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2172"},{"key":"bibr28-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz360.2171"},{"key":"bibr29-1060028020942218","unstructured":"Centers for Disease Control and Prevention. Breastfeeding. Human immunodeficiency virus (HIV). Accessed May 1, 2020. https:\/\/www.cdc.gov\/breastfeeding\/breastfeeding-special-circumstances\/maternal-or-infant-illnesses\/hiv.html"},{"key":"bibr30-1060028020942218","unstructured":"European Medicines Agency. Annex I: Summary of product characteristics. Trogarzo. Accessed May 23, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trogarzo-epar-product-information_en.pdf"},{"key":"bibr31-1060028020942218","unstructured":"Theratechnologies. Trogarzo\u00ae remains effective close to a decade after treatment initiation. Published November 7, 2019. Accessed May 1, 2020. https:\/\/www.theratech.com\/en\/trogarzo-remains-effective-close-to-a-decade-after-treatment-initiation\/"},{"key":"bibr32-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018793252"},{"key":"bibr33-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1570131"},{"key":"bibr34-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0360-7"},{"key":"bibr35-1060028020942218","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002241"},{"key":"bibr36-1060028020942218","volume-title":"Paper presented at: 17th European AIDS Conference","author":"Miller W"},{"key":"bibr37-1060028020942218","volume-title":"Red Book Online. Micromedex Healthcare Series [database online]","author":"Ibalizumab","year":"2020"},{"key":"bibr38-1060028020942218","volume-title":"Red Book Online. Micromedex Healthcare Series [database online]","author":"Bictegravir\/tenofovir alafenamide\/emtricitabine","year":"2020"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020942218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020942218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020942218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:43Z","timestamp":1777374943000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020942218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1177\/1060028020942218"],"URL":"https:\/\/doi.org\/10.1177\/1060028020942218","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]}}}